Eculizumab
Top View
- Bla 125166/172 Soliris® (Eculizumab)
- Early Institution of Tocilizumab Titration in Non-Critical Hospitalized COVID-19 Pneumonitis (COVIDOSE)
- Ten-Year Outcome of Eculizumab in Kidney Transplant Recipients With
- Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: a Multicenter Study
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- Journal of Immunological Methods Multiplexed Monitoring Of
- Antibody Drug Nomenclature: -Umab -Zumab -Ximab
- Soliris (Eculizumab) Is Supplied As 300 Mg Single-Use Vials Containing 30 Ml of 10 Mg/Ml Sterile, 262 Preservative-Free Soliris Solution Per Vial
- (12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
- SPECIALTY MEDICATION ADMINISTRATION – SITE of CARE REVIEW GUIDELINES Policy Number: PHARMACY 276.16 T2 Effective Date: January 1, 2018
- Case Report Renal and Neurological Response with Eculizumab in A
- Successful Use of Eculizumab to Treat Atypical Hemolytic Uremic Syndrome in Patients with Inflammatory Bowel Disease Ramy M
- Complement Inhibitors
- Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: a Meta-Analysis of Randomized Control Trials
- SOLIRIS® (ECULIZUMAB) Policy Number: PHARMACY 277.8 T2 Effective Date: February 1, 2018
- Quantification of Multiple Therapeutic Mabs in Serum Using Microlc-ESI-Q-TOF Mass Spectrometry
- Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
- Eculizumab > Printer-Friendly PDF